178 related articles for article (PubMed ID: 19925601)
1. Angiokeratoma regression in a Fabry disease after treatment with agalsidase-beta: clinical effectiveness marker?
Fauchais AL; Prey S; Ouatara B; Vidal E; Sparsa A
J Eur Acad Dermatol Venereol; 2010 Jun; 24(6):737-8. PubMed ID: 19925601
[No Abstract] [Full Text] [Related]
2. Safe and Successful Treatment With Agalsidase Beta During Pregnancy in Fabry Disease.
Senocak Tasci E; Bicik Z
Iran J Kidney Dis; 2015 Sep; 9(5):406-8. PubMed ID: 26338166
[TBL] [Abstract][Full Text] [Related]
3. Enzyme replacement therapy in two Japanese siblings with Fabry disease, and its effectiveness on angiokeratoma and neuropathic pain.
Furujo M; Kubo T; Kobayashi M; Ohashi T
Mol Genet Metab; 2013 Nov; 110(3):405-10. PubMed ID: 23906479
[TBL] [Abstract][Full Text] [Related]
4. Treatment with agalsidase beta during pregnancy in Fabry disease.
Politei JM
J Obstet Gynaecol Res; 2010 Apr; 36(2):428-9. PubMed ID: 20492401
[TBL] [Abstract][Full Text] [Related]
5. Effects of Enzyme Replacement Therapy and Antidrug Antibodies in Patients with Fabry Disease.
Lenders M; Brand E
J Am Soc Nephrol; 2018 Sep; 29(9):2265-2278. PubMed ID: 30093456
[No Abstract] [Full Text] [Related]
6. Time to treatment benefit for adult patients with Fabry disease receiving agalsidase β: data from the Fabry Registry.
Ortiz A; Abiose A; Bichet DG; Cabrera G; Charrow J; Germain DP; Hopkin RJ; Jovanovic A; Linhart A; Maruti SS; Mauer M; Oliveira JP; Patel MR; Politei J; Waldek S; Wanner C; Yoo HW; Warnock DG
J Med Genet; 2016 Jul; 53(7):495-502. PubMed ID: 26993266
[TBL] [Abstract][Full Text] [Related]
7. Enzyme replacement therapy in Fabry disease: comparison of agalsidase alfa and agalsidase beta.
Mehta A; Beck M; Kampmann C; Frustaci A; Germain DP; Pastores GM; Sunder-Plassmann G
Mol Genet Metab; 2008; 95(1-2):114-5. PubMed ID: 18701330
[No Abstract] [Full Text] [Related]
8. Fabry disease: clinical outcomes of agalsidase enzyme replacement therapies.
Wanner C
Int J Clin Pract; 2007 Jul; 61(7):1234-5; author reply 1235. PubMed ID: 17577304
[No Abstract] [Full Text] [Related]
9. Angiokeratomas and treatment with enzyme replacement therapy in a patient with Fabry disease.
Merzel Šabović EK; Žerjav Tanšek M; Grošelj U; Dragoš V
Acta Dermatovenerol Alp Pannonica Adriat; 2020 Jun; 29(2):89-91. PubMed ID: 32566958
[TBL] [Abstract][Full Text] [Related]
10. Beneficial effects of long-term enzyme replacement therapy in a child with Fabry disease.
Martin-Suárez I; Suárez-Marrero C
Int J Clin Pract; 2010 Jun; 64(7):995. PubMed ID: 20584233
[No Abstract] [Full Text] [Related]
11. Home infusion program for Fabry disease: experience with agalsidase alfa in Argentina.
Kisinovsky I; Cáceres G; Coronel C; Reisin R
Medicina (B Aires); 2013; 73(1):31-4. PubMed ID: 23335703
[TBL] [Abstract][Full Text] [Related]
12. Fabry disease under enzyme replacement therapy-new insights in efficacy of different dosages.
Krämer J; Lenders M; Canaan-Kühl S; Nordbeck P; Üçeyler N; Blaschke D; Duning T; Reiermann S; Stypmann J; Brand SM; Gottschling T; Störk S; Wanner C; Sommer C; Brand E; Weidemann F
Nephrol Dial Transplant; 2018 Aug; 33(8):1362-1372. PubMed ID: 29186537
[TBL] [Abstract][Full Text] [Related]
13. Letter concerning "Enzyme replacement therapy in a patient with Fabry disease and the development of IgE antibodies against agalsidase beta but not agalsidase alpha", by Tanaka et al.
Linthorst GE; Aerts JM
J Inherit Metab Dis; 2011 Feb; 34(1):237-8. PubMed ID: 20938807
[No Abstract] [Full Text] [Related]
14. Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy.
van Breemen MJ; Rombach SM; Dekker N; Poorthuis BJ; Linthorst GE; Zwinderman AH; Breunig F; Wanner C; Aerts JM; Hollak CE
Biochim Biophys Acta; 2011 Jan; 1812(1):70-6. PubMed ID: 20851180
[TBL] [Abstract][Full Text] [Related]
15. Enzyme replacement therapy with agalsidase alfa in pregnant women with Fabry disease.
Kalkum G; Macchiella D; Reinke J; Kölbl H; Beck M
Eur J Obstet Gynecol Reprod Biol; 2009 May; 144(1):92-3. PubMed ID: 19233535
[No Abstract] [Full Text] [Related]
16. Clinical course of patients with Fabry disease who were switched from agalsidase-β to agalsidase-α.
Tsuboi K; Yamamoto H
Genet Med; 2014 Oct; 16(10):766-72. PubMed ID: 24651606
[TBL] [Abstract][Full Text] [Related]
17. [Utility of enzyme replacement therapy in Fabry disease].
Politei JM; Dubrovsky A
Med Clin (Barc); 2010 Apr; 134(9):402-5. PubMed ID: 20138313
[TBL] [Abstract][Full Text] [Related]
18. Consequences of a global enzyme shortage of agalsidase beta in adult Dutch Fabry patients.
Smid BE; Rombach SM; Aerts JM; Kuiper S; Mirzaian M; Overkleeft HS; Poorthuis BJ; Hollak CE; Groener JE; Linthorst GE
Orphanet J Rare Dis; 2011 Oct; 6():69. PubMed ID: 22041095
[TBL] [Abstract][Full Text] [Related]
19. The use of agalsidase alfa enzyme replacement therapy in the treatment of Fabry disease.
Morel CF; Clarke JT
Expert Opin Biol Ther; 2009 May; 9(5):631-9. PubMed ID: 19368525
[TBL] [Abstract][Full Text] [Related]
20. Spotlight on agalsidase beta in Fabry disease.
Keating GM; Simpson D
BioDrugs; 2007; 21(4):269-71. PubMed ID: 17628124
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
